Tenet Healthcare (THC) Stock Slides as Market Rises: Facts to Know Before You Trade

Zacks Zacks Открыть на Zacks
Tenet Healthcare (THC) Stock Slides as Market Rises: Facts to Know Before You Trade

In the latest trading session, Tenet Healthcare (THC) closed at $192.99, marking a -1.15% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 1.02%. At the same time, the Dow added 0.63%, and the tech-heavy Nasdaq gained 1.23%.

The hospital operator's stock has dropped by 14.23% in the past month, falling short of the Medical sector's loss of 4.81% and the S&P 500's gain of 0.63%.

The investment community will be closely monitoring the performance of Tenet Healthcare in its forthcoming earnings report. The company is scheduled to release its earnings on April 30, 2026. In that report, analysts expect Tenet Healthcare to post earnings of $4.19 per share. This would mark a year-over-year decline of 3.9%. Our most recent consensus estimate is calling for quarterly revenue of $5.39 billion, up 3.15% from the year-ago period.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $17.3 per share and revenue of $22.01 billion, indicating changes of +3.1% and +3.27%, respectively, compared to the previous year.

It's also important for investors to be aware of any recent modifications to analyst estimates for Tenet Healthcare. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Currently, Tenet Healthcare is carrying a Zacks Rank of #3 (Hold).

Digging into valuation, Tenet Healthcare currently has a Forward P/E ratio of 11.29. This denotes no noticeable deviation relative to the industry average Forward P/E of 11.29.

It is also worth noting that THC currently has a PEG ratio of 0.94. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Hospital stocks are, on average, holding a PEG ratio of 0.94 based on yesterday's closing prices.

The Medical - Hospital industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 56, positioning it in the top 23% of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Quantum Computing Stocks Set To Soar

Artificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.

Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power , you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.

Access the Report Free Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Tenet Healthcare Corporation (THC): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research